Literature DB >> 24510315

Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis.

P Bossi1, E Orlandi2, R Miceli3, F Perrone4, M Guzzo5, L Mariani3, R Granata6, L Locati6, C Fallai2, B Cortelazzi4, S Pilotti4, G Scaramellini5, A Gloghini4, L Licitra6.   

Abstract

BACKGROUND: To date, no treatment modality has been identified as more effective for oropharyngeal cancer (OPC), and no predictive factors are known to guide treatment decision for this disease. This retrospective study evaluates the differential effects of diverse treatment options for OPC according to patient risk profiles. PATIENTS AND METHODS: We considered two series of locally advanced squamous cell OPC patients treated with either surgery followed by radiotherapy (surgical series) or chemoradiation (CRT) with/without induction docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy (CRT series). Smoking habits, tumor p16 expression/human papillomavirus (HPV) status and T and N stage were analyzed to stratify the patients according to Ang's risk profile (low, intermediate and high risk). Overall survival (OS) and disease-free survival were calculated with the Kaplan-Meier method.
RESULTS: Globally, 171 patients were considered, 56 in surgical and 115 in CRT series. Patients were stratified in low- (20% of surgical and CRT groups), intermediate- (23% and 41%) and high-risk (57% and 39%) groups. In the surgical series, 5-year OS was 54.5%, 46.9% and 40.0% in low, intermediate and high Ang's risk profiles, respectively, whereas in the CRT series those were 100%, 78.9% and 46.7%, respectively. In the multivariable analyses, adjusting for inhomogeneity between the treatment group, the CRT effect was significantly higher in the low- and intermediate-risk groups (P-value for the interaction treatment risk group = 0.034 in the OS analysis).
CONCLUSIONS: In this retrospective analysis, low- and intermediate-risk OPC patients had a better survival when treated with CRT compared with open surgery followed by radiation therapy. These data suggest that different treatment approaches might be essential in determining outcome results.

Entities:  

Keywords:  chemoradiation; human papilloma virus; oropharyngeal cancer; risk profile; survival

Mesh:

Substances:

Year:  2014        PMID: 24510315      PMCID: PMC4433530          DOI: 10.1093/annonc/mdu004

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  21 in total

1.  High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma.

Authors:  Lisa Licitra; Federica Perrone; Paolo Bossi; Simona Suardi; Luigi Mariani; Raffaella Artusi; Maria Oggionni; Chiara Rossini; Giulio Cantù; Massimo Squadrelli; Pasquale Quattrone; Laura D Locati; Cristiana Bergamini; Patrizia Olmi; Marco A Pierotti; Silvana Pilotti
Journal:  J Clin Oncol       Date:  2006-12-20       Impact factor: 44.544

2.  Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients.

Authors:  L Licitra; F Perrone; E Tamborini; L Bertola; C Ghirelli; T Negri; M Orsenigo; P Filipazzi; E Pastore; M Pompilio; P Bossi; L D Locati; G Cantu'; G Scaramellini; S Pilotti; E Tagliabue
Journal:  Ann Oncol       Date:  2011-02-22       Impact factor: 32.976

3.  Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study.

Authors:  R Granata; R Miceli; E Orlandi; F Perrone; B Cortelazzi; M Franceschini; L D Locati; P Bossi; C Bergamini; A Mirabile; L Mariani; P Olmi; G Scaramellini; P Potepan; P Quattrone; K K Ang; L Licitra
Journal:  Ann Oncol       Date:  2011-11-24       Impact factor: 32.976

4.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site.

Authors:  Pierre Blanchard; Bertrand Baujat; Victoria Holostenco; Abderrahmane Bourredjem; Charlotte Baey; Jean Bourhis; Jean-Pierre Pignon
Journal:  Radiother Oncol       Date:  2011-06-16       Impact factor: 6.280

5.  Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial.

Authors:  M R Posner; J H Lorch; O Goloubeva; M Tan; L M Schumaker; N J Sarlis; R I Haddad; K J Cullen
Journal:  Ann Oncol       Date:  2011-02-11       Impact factor: 32.976

6.  Transoral resection of pharyngeal cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia.

Authors:  David J Adelstein; John A Ridge; David M Brizel; F Christopher Holsinger; Bruce H Haughey; Brian O'Sullivan; Eric M Genden; Jonathan J Beitler; Gregory S Weinstein; Harry Quon; Douglas B Chepeha; Robert L Ferris; Randal S Weber; Benjamin Movsas; John Waldron; Val Lowe; Scott Ramsey; Judith Manola; Bevan Yueh; Thomas E Carey; Justin E Bekelman; Andre A Konski; Eric Moore; Arlene Forastiere; David E Schuller; Jean Lynn; Claudio Dansky Ullmann
Journal:  Head Neck       Date:  2012-09-26       Impact factor: 3.147

7.  Population-based evidence of increased survival in human papillomavirus-related head and neck cancer.

Authors:  Mari Nygård; Bjarte Aagnes; Freddie Bray; Bjørn Møller; Jon Mork
Journal:  Eur J Cancer       Date:  2012-04-18       Impact factor: 9.162

8.  Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus.

Authors:  Boudewijn J M Braakhuis; Peter J F Snijders; Willem-Jan H Keune; Chris J L M Meijer; Henrique J Ruijter-Schippers; C René Leemans; Ruud H Brakenhoff
Journal:  J Natl Cancer Inst       Date:  2004-07-07       Impact factor: 13.506

9.  Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy.

Authors:  A M Hong; T A Dobbins; C S Lee; D Jones; G B Harnett; B K Armstrong; J R Clark; C G Milross; J Kim; C J O'Brien; B R Rose
Journal:  Br J Cancer       Date:  2010-10-19       Impact factor: 7.640

10.  Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer.

Authors:  Maura L Gillison; Qiang Zhang; Richard Jordan; Weihong Xiao; William H Westra; Andy Trotti; Sharon Spencer; Jonathan Harris; Christine H Chung; K Kian Ang
Journal:  J Clin Oncol       Date:  2012-05-07       Impact factor: 44.544

View more
  12 in total

Review 1.  The prevalence of human papillomavirus in squamous cell carcinoma of unknown primary site metastatic to neck lymph nodes: a systematic review.

Authors:  Paolo Boscolo-Rizzo; Lea Schroeder; Salvatore Romeo; Michael Pawlita
Journal:  Clin Exp Metastasis       Date:  2015-09-10       Impact factor: 5.150

2.  Definitive radiochemotherapy or initial surgery for oropharyngeal cancer : To what extent can p16 expression be used in the decision process?

Authors:  Anouchka Modesto; Thibaut Galissier; Amélie Lusque; Jean-Pierre Delord; Emmanuelle Uro-Coste; Jérôme Sarini; Frédéric Mouchet; Raphaël Lopez; Anne Laprie; Pierre Graff; Sébastien Vergez; Michel Rives
Journal:  Strahlenther Onkol       Date:  2019-03-15       Impact factor: 3.621

3.  Meta-analysis of survival in patients with HNSCC discriminates risk depending on combined HPV and p16 status.

Authors:  Annekatrin Coordes; Klaus Lenz; Xu Qian; Minoo Lenarz; Andreas M Kaufmann; Andreas E Albers
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-07-31       Impact factor: 2.503

4.  Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinoma.

Authors:  Timothy Cooper; Vincent L Biron; David Fast; Raymond Tam; Thomas Carey; Maya Shmulevitz; Hadi Seikaly
Journal:  J Otolaryngol Head Neck Surg       Date:  2015-02-24

5.  Human papillomavirus association is the most important predictor for surgically treated patients with oropharyngeal cancer.

Authors:  Steffen Wagner; Claus Wittekindt; Shachi Jenny Sharma; Nora Wuerdemann; Theresa Jüttner; Miriam Reuschenbach; Elena-Sophie Prigge; Magnus von Knebel Doeberitz; Stefan Gattenlöhner; Ernst Burkhardt; Jörn Pons-Kühnemann; Jens Peter Klussmann
Journal:  Br J Cancer       Date:  2017-05-04       Impact factor: 7.640

6.  The rationale for HPV-related oropharyngeal cancer de-escalation treatment strategies.

Authors:  Małgorzata Wierzbicka; Krzysztof Szyfter; Piotr Milecki; Krzysztof Składowski; Rodryg Ramlau
Journal:  Contemp Oncol (Pozn)       Date:  2015-09-28

7.  Meta analysis: HPV and p16 pattern determines survival in patients with HNSCC and identifies potential new biologic subtype.

Authors:  Andreas E Albers; Xu Qian; Andreas M Kaufmann; Annekatrin Coordes
Journal:  Sci Rep       Date:  2017-12-01       Impact factor: 4.379

8.  The evolution of the epidemiological landscape of head and neck cancer in Italy: Is there evidence for an increase in the incidence of potentially HPV-related carcinomas?

Authors:  Paolo Boscolo-Rizzo; Manuel Zorzi; Annarosa Del Mistro; Maria Cristina Da Mosto; Giancarlo Tirelli; Carlotta Buzzoni; Massimo Rugge; Jerry Polesel; Stefano Guzzinati
Journal:  PLoS One       Date:  2018-02-07       Impact factor: 3.240

9.  High-throughput testing in head and neck squamous cell carcinoma identifies agents with preferential activity in human papillomavirus-positive or negative cell lines.

Authors:  Farhad Ghasemi; Morgan Black; John W Barrett; Paul C Boutros; Anthony C Nichols; Ren X Sun; Frederick Vizeacoumar; Nicole Pinto; Kara M Ruicci; John Yoo; Kevin Fung; Danielle MacNeil; David A Palma; Eric Winquist; Joe S Mymryk; Laurie A Ailles; Alessandro Datti
Journal:  Oncotarget       Date:  2018-05-25

10.  Comparison of PI3K Pathway in HPV-Associated Oropharyngeal Cancer With and Without Tobacco Exposure.

Authors:  Si-Young Kiessling; Martina Anja Broglie; Alex Soltermann; Gerhard Frank Huber; Sandro Johannes Stoeckli
Journal:  Laryngoscope Investig Otolaryngol       Date:  2018-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.